Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by prophetoffactzon Aug 17, 2022 7:06pm
204 Views
Post# 34903534

The next major step in MS:

The next major step in MS:

Research Summary: Repurposing the cardiac glycoside digoxin to stimulate myelin regeneration in chemically-induced and immune-mediated mouse models of multiple sclerosis

The ability to repair myelin damage in multiple sclerosis represents the next major step forward in the treatment of the disease. 

FINDING #1:  Digoxin was able to promote the repair of damaged myelin in mice.  

FINDING #2:  Digoxin was found to be ineffective at suppressing the autoimmune response in an animal model of multiple sclerosis.  This indicates that the benefits observed through the use of digoxin relate to its ability to promote myelin repair and show it does not have any impact on disease progression.


FINDING #3:  A combined treatment approach using digoxin and a second therapy designed to stop new damage to the central nervous system produced better improvements in clinical symptoms in an animal model of multiple sclerosis.  This suggests that the best strategy may involve using two treatments:  one to stop new damage, such as many of the existing therapies for multiple sclerosis, and one to repair existing damage (i.e. a remyelination therapy).

<< Previous
Bullboard Posts
Next >>